Advantages of Robot-Assisted Laparoscopic Radical Prostatectomy in Obese Patients: Comparison with the Open Procedure.
10.4111/kju.2012.53.8.536
- Author:
Jae Jun BAE
1
;
Seok Hwan CHOI
;
Tae Gyun KWON
;
Tae Hwan KIM
Author Information
1. Department of Urology, Kyungpook National University School of Medicine, Daegu, Korea. doctork@knu.ac.kr
- Publication Type:Original Article
- Keywords:
Obesity;
Prostatectomy;
Robotics
- MeSH:
Body Mass Index;
Humans;
Obesity;
Prostatectomy;
Prostatic Neoplasms;
Retrospective Studies;
Risk Factors;
Robotics
- From:Korean Journal of Urology
2012;53(8):536-540
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Obesity has been suggested as a risk factor for worse perioperative outcomes, especially in radical prostatectomy, in several studies. However, the impact of obesity on perioperative outcomes has not yet been well elucidated for robot-assisted laparoscopic radical prostatectomy (RALP). We evaluated whether obesity had an adverse effect on outcomes following RALP compared with retropubic radical prostatectomy (RRP). MATERIALS AND METHODS: From April 2008 to May 2011, 181 patients underwent radical prostatectomy (RALP, 111; RRP, 70). These patients were subdivided into two groups according to body mass index (BMI): the nonobese group (BMI, 25 kg/m2 or less) and the obese group (BMI, greater than 25 kg/m2). Perioperative outcomes in RALP and RRP were retrospectively compared between the two groups. RESULTS: In RRP, patients in the obese group (n=20) showed greater blood loss and a higher complication rate than did those in the nonobese group (n=50). However, in RALP, no statistically significant differences in perioperative outcomes were observed between the obese (n=37) and the nonobese (n=74) groups. RALP showed less blood loss and a lower complication rate in both the obese and nonobese groups than did RRP. CONCLUSIONS: RALP is thought to be a more effective and safer procedure in obese patients compared with traditional open radical prostatectomy. In the management of obese patients with localized prostate cancer, RALP should be considered as a primary choice for treatment.
